Delmas PD, Rizzoli R, Cooper C, Reginster JY (2005) Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation. Osteoporos Int 16:1–5

PubMed  Google Scholar 

Kanis JA, Borgstrom F, De Laet C et al (2005) Assessment of fracture risk. Osteoporos Int. https://doi.org/10.1007/s00198-004-1780-5

Article  PubMed  Google Scholar 

Kanis JA, Cooper C, Rizzoli R, Reginster JY (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3–44

CAS  PubMed  Google Scholar 

Chandran M, Mitchell PJ, Amphansap T, Bhadada SK, Chadha M et al (2021) Development of the Asia Pacific Consortium on Osteoporosis (APCO) Framework: clinical standards of care for the screening, diagnosis, and management of osteoporosis in the Asia-Pacific region. Osteoporos Int 32:1249–1275

CAS  PubMed  PubMed Central  Google Scholar 

Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS et al (2020) American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis – 2020 Update Executive Summary. Endocr Pract 26:564–570

PubMed  Google Scholar 

Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF) (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3–44

CAS  PubMed  Google Scholar 

Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 104:1595–1622

PubMed  Google Scholar 

Nakamura T, Sugimoto T, Nakano T et al (2012) Randomized Teriparatide [human parathyroid hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97:3097–3106

CAS  PubMed  Google Scholar 

Yamane H, Takakura A, Shimadzu Y et al (2017) Acute development of cortical porosity and endosteal naïve bone formation from the daily but not weekly short-term administration of PTH in rabbit. PLoS ONE 12:e0175329. https://doi.org/10.1371/journal.pone.0175329

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vahle JL, Sato M, Long GG et al (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol Pathol 30:312–321

CAS  PubMed  Google Scholar 

Eastell R, Nickelsen T, Marin F et al (2009) Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res 24:726–736

CAS  PubMed  Google Scholar 

Adami S, San Martin J, Muñoz-Torres M et al (2008) Effect of raloxifene after recombinant teriparatide [hPTH(1–34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int 19:9

Google Scholar 

Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 334:1434–1441

Google Scholar 

Kendler D, Marin F, Zerbini CA et al (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicenter, double-blind, double dummy, randomized controlled trial. Lancet 391:230–240

CAS  PubMed  Google Scholar 

Silverman S, Langdahl BL, Fujiwara S et al (2019) Reduction of hip and other fractures in patients receiving teriparatide in real-world clinical practice: integrated analysis of four prospective observational studies. Calcif Tissue Int 104:193–200

CAS  PubMed  Google Scholar 

Leder ZL, Neer RM, Wyland JJ et al (2009) Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab 94:2915–2921

CAS  PubMed  PubMed Central  Google Scholar 

Rittmaster RS, Bolognese M, Ettinger MP et al (2000) Enhancement of bone mass in osteoporotic women eith parathyroid hormone followed by alendronate. J Clin Endoclinol Metab 85:2129–2134

CAS  Google Scholar 

Kurland ES, Heller SL, Diamond B et al (2004) The importance of bisphosphonate in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1–34)]. Osteoporos Int 15:992–997

CAS  PubMed  Google Scholar 

Ebina K, Hashimoto K, Kashii M et al (2017) The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis. J Bone Miner Res 35:91–98

CAS  Google Scholar 

Yamamoto T, Hasegawa T, Sasaki M et al (2016) Frequency of teriparatide administration affects the histological pattern of bone formation in young adult male mice. Endocrinology 157:2604–2620

CAS  PubMed  Google Scholar 

Zebaze R, Takao-Kawabata R, Peng Y et al (2017) Increased cortical porosity is associated with daily, not weekly, administration of equivalent doses of teriparatide. Bone 99:80–84

CAS  PubMed  Google Scholar 

Sugimoto T, Shiraki M, Nakano T et al (2013) Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial. Curr Med Res Opin 29:195–203

CAS  PubMed  Google Scholar 

Black DM, Bilezikian JP, Ensrud KE et al (2005) One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med 353:555–565

CAS  PubMed  Google Scholar 

Tanaka S, Mori S, Hagino H, Sugimoto T (2020) Design of a randomized trial of teriparatide followed by alendronate: Japanese Osteoporosis Intervention Trial-05 (JOINT-05). J Bone Miner Metab 38:412–417

CAS  PubMed  Google Scholar 

Hagino H, Sugimoto T, Tanaka S et al (2021) A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05. Osteoporos Int 32:2301–2311

CAS  PubMed  PubMed Central  Google Scholar 

Mori S, Hagino H, Sugimoto T et al (2023) Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05. Osteoporos Int 34:189–199

CAS  PubMed  Google Scholar 

Gilsenan A, Midkiff K, Harris D et al (2020) Assessing the incidence of osteosarcoma among teriparatide users based on Medicare Part D and US State Cancer Registry Data. Pharmacoepidemiol Drug Saf 29:1616–1626

CAS  PubMed  PubMed Central  Google Scholar 

Gilsenan A, Midkiff K, Harris D et al (2020) Teriparatide Did Not Increase Adult Osteosarcoma in a 15-Year US Postmarketing Surveillance Study. J Bone Miner Res. https://doi.org/10.1002/jbmr.4188

Article  PubMed  Google Scholar